Publish the evidence.
A full, transparent assessment of the scientific record before any restriction is proposed or adopted.
The appeal
An open appeal by an international coalition of patient organisations · published June 2026 · open for signatures and for additional organisations to join.
Read or download
This appeal does not assert a free-standing legal right to a product. It concerns how a proposed administrative restriction of CBD would harm patients’ established rights — their autonomy, their dignity, and their right to transparent, evidence-based decision-making.
The full appeal text is maintained and approved as its own document. This page hosts the approved PDF in six languages; the executive summary below lists what the coalition asks.
The appeal (PDF): EN CZ ES FR DE ITA full, transparent assessment of the scientific record before any restriction is proposed or adopted.
No administrative measures without open public debate, a proportionality test, and a patient-impact assessment.
Patients’ right to make informed, evidence-based decisions about their own treatment.
Proportionate rules: quality standards, contaminant testing, clear labelling, age restrictions where relevant.
Enforcement against synthetic cannabinoids sold as “collector’s items” — not against tested products patients rely on.
Patient organisations formally consulted in every decision that affects access to treatment.
INCB issues internal PP Notice No. 1/2026 on cannabidiol.
Public statements in several states frame CBD as a “precursor of synthetic drugs”.
The Czech government moves its CBD restriction proposal into the inter-ministerial comment procedure.
The coalition publishes this appeal.
Comment-procedure deadline; the coalition files its formal submission.
The final entry stays a placeholder until the deadline is confirmed.
Sharing graphics? Download the influencer kit (ZIP) or browse the press & supporter kit.